Welcome to our dedicated page for Biophytis SA American Depositary Share (0.01 Euro) SEC filings (Ticker: BPTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biophytis SA (BPTS) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Biophytis files Form 6‑K current reports under the Securities Exchange Act of 1934, which furnish press releases and other information for U.S. investors about its clinical programs, financing transactions and financial reporting.
For a clinical-stage biotechnology company like Biophytis, these filings are a key source for understanding how its lead candidate BIO101 (20-hydroxyecdysone) progresses through development. Recent 6‑K filings referenced in the data include announcements about phase 2 and phase 3 trial strategies in sarcopenia and obesity, regulatory authorizations from European agencies, and participation in industry conventions. Other 6‑Ks report on the publication of annual financial results, the status of bond financing lines, and temporary trading suspensions, giving investors insight into the company’s operational and capital position.
Because Biophytis uses bond structures that can convert into equity, filings describing these arrangements help readers evaluate potential dilution and financing risk. The 6‑Ks also complement the company’s home-market disclosures by summarizing major clinical milestones, such as IND approvals for the OBA obesity study or regulatory clearances to initiate sarcopenia trials, in a format tailored to U.S. markets.
On Stock Titan, Biophytis filings are updated as new documents appear on EDGAR. Each filing can be reviewed in full, and AI-powered tools can assist in highlighting the main topics, such as trial status, financing terms or changes in reporting timelines. This makes it easier to navigate Biophytis’s multi-year filing history and to locate specific information about its age-related disease programs, financial communications and corporate actions tied to the BPTS symbol.
Biophytis S.A. filed a report noting that it has issued a press release unveiling its Phase 3 sarcopenia trial strategy for its investigational product BIO101 in Europe and Asia. The filing mainly serves to furnish this press release to investors as an exhibit.
Biophytis S.A. reports that it has obtained authorization from the European Medicines Agency (EMA) to launch a Phase 2 clinical trial in obesity. The company communicated this development through a press release, which is included as an exhibit to the report for additional detail.
Biophytis S.A. filed a Form 6-K to share a new clinical development update. The company reported that it issued a press release on September 1, 2025 unveiling its Phase-2 obesity trial strategy using BIO101 in Europe and Brazil.
The press release is attached as Exhibit 99.1 to the report, providing more detail on how Biophytis plans to advance BIO101 in obesity through this Phase-2 program in those regions.
Biophytis S.A. reported that it has received approval from the European Medicines Agency (EMA) and Belgian regulators to start a Phase 3 clinical trial in sarcopenia, a muscle loss condition often linked to aging. This clearance allows the company to begin late-stage testing of its sarcopenia treatment candidate in Europe, an important step in evaluating whether the therapy can demonstrate meaningful clinical benefit in a larger patient population.
The update was communicated through a press release dated August 28, 2025, which is attached to the report as an exhibit.
Biophytis S.A. (ticker: BPTS) filed a Form 6-K on June 24, 2025, to alert investors that, on June 19, 2025, it issued a press release announcing the temporary suspension of trading of its shares. The filing attaches the press release as Exhibit 99.1. No further details—such as the duration, cause, or expected resolution of the suspension—are provided in the submission. The only signatory is Chairman and CEO Stanislas Veillet. Because the document offers no financial statements, earnings data, or transaction details, its sole material disclosure is the trading halt.